Medicine and Dentistry
Glioblastoma
100%
Tumor Treating Fields
51%
Neoplasm
49%
Ganglioglioma
45%
Incision
43%
Fluorine-18
43%
Pyruvate Kinase
36%
Colectomy
34%
Clinical Trial
33%
Radiation Therapy
31%
Laparoscopic Surgery
29%
Diseases
28%
Malignant Neoplasm
25%
positron emission tomographic scan
24%
Radioactive Tracer
23%
Intracranial Tumor
22%
Operation Duration
22%
Blood Brain Barrier
20%
Hemicolectomy
17%
Magnetic Resonance Imaging
17%
Tumor Progression
17%
Colorectal Surgery
16%
Overall Survival
15%
Surgery
15%
Surgeon
14%
Body Mass Index
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Dosimetry
14%
Molecular Imaging
14%
Advance Care Planning
14%
Learning Curve
14%
Remifentanil
14%
Spinal Cord Metastasis
14%
Ileo-Anal Pouch
14%
Thrombocyte Function
14%
Water-Electrolyte Imbalance
14%
Cancer
13%
Bleeding
12%
Diffuse Large B-Cell Lymphoma
12%
Minimally Invasive Procedure
12%
Temozolomide
11%
Proctocolectomy
10%
Peroperative Complication
10%
Pelvis
10%
Propofol
9%
Adenosine Diphosphate
9%
Sevoflurane
9%
Surgical Anastomosis
9%
Dermatitis
9%
Diagnosis
9%
Keyphrases
Glioblastoma
66%
Tumor Treating Fields
58%
Pyruvate Kinase M2 (PKM2)
26%
Glioma
24%
Molecular Imaging
21%
Radiation Therapy
21%
Sevoflurane
18%
Total Intravenous Anesthesia
17%
Alternating Electric Field
16%
High-grade Glioma
16%
Inhalation Anesthesia
15%
Positron Emission Tomography
15%
Glioblastoma Cells
15%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
15%
Mechanism of Action
15%
Tumor
15%
Chimeric Antigen Receptor T-cell Therapy
14%
Field Strength
14%
Remifentanil
13%
Radiotracer
13%
Overall Survival
13%
Anesthesia
12%
Robot-assisted Laparoscopy
10%
Informed Consent
10%
Propofol-remifentanil
10%
Temozolomide
9%
Healthy Volunteers
9%
Imaging Tracer
9%
Clinical Translation
9%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
Pembrolizumab
9%
Ktrans
9%
Tumor Progression
9%
Blood-brain Barrier Permeability
9%
Radiation Chemotherapy
9%
Right Hemicolectomy
8%
Intraoperative Conversion
8%
Cell Membrane
8%
Isocitrate Dehydrogenase 1 (IDH1)
8%
Anticancer Activity
8%
Apoptosis
8%
Length of Hospital Stay
8%
Glycolysis
8%
Synergistic Effect
7%
Electric Field Treatment
7%
Field-induced
7%
Fetal Rat Brain
7%
Promoter Methylation
7%
Tumor Burden
7%
Conivaptan
7%